Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GB:0MGB)
:0MGB
0MGB Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr1,247.50 - kr2,123.00
Previous CloseN/A
Volume5.49K
Average Volume (3M)29.12K
Market Cap
kr79.53B
Enterprise Valuekr75.38B
Total Cash (Recent Filing)kr9.86B
Total Debt (Recent Filing)kr1.03B
Price to Earnings (P/E)10.3
Beta0.72
Next Earnings
May 08, 2025EPS Estimate
14.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)122.59
Shares Outstanding66,197,240
10 Day Avg. Volume55,067
30 Day Avg. Volume29,121
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)N/A
Price to Sales (P/S)0.10
Price to Cash Flow (P/CF)0.90
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr1,981.38Price Target Upside57.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Benchmark SurpassingGenmab remains confident in surpassing Elahere benchmark, with strong data relative to AbbVie's Elahere.
Investor ConfidenceManagement is really beginning to try and increase investor focus on pipeline assets, with peak sales guide across three key assets and clearer commentary on next data.
Market ConfidenceAnalyst reiterates a BUY rating with a price objective significantly higher than the current price, indicating confidence in stock growth.
Bears Say
Growth ProspectsThe new price target implies a 47% discount to global biotech peers, indicating lower growth prospects.
Pipeline NewsThe recent disappointing ‘Hexabody’ pipeline news has led to a downgrade of Genmab's stock to underperform.
Revenue ImpactThe share price does not fully account for the loss of exclusivity of Darzalex, which could significantly impact future revenues.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
13.01%
Mutual Funds
<0.01% Other Institutional Investors
78.85% Public Companies and
Individual Investors
0MGB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest share price was kr1247.50 and its highest was kr2123.00 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is kr79.53B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is May 08, 2025 which is in 32 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Feb 12, 2025. The company reported kr60.08 earnings per share for the quarter, beating the consensus estimate of kr26.701 by kr33.379.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 14.75.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 66,197,240 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of kr60.08 in its last earnings report, beating expectations of kr26.701. Following the earnings report the stock price went up 0.214%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GB:0MGB
---
Company Description
Genmab A/S
Genmab is a Copenhagen-based cancer drug developer, best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company also has several pipeline candidates targeting other oncologic indications and autoimmune diseases.
---
0MGB Stock 12 Month Forecast
Average Price Target
kr1,981.38
▲(57.45% Upside)
Technical Analysis
Best Analysts Covering 0MGB
1 Year
1 Year Success Rate
18/38 ratings generated profit
1 Year Average Return
+7.96%
reiterated a buy rating 26 days ago
Copying Emily Field's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +7.96% per trade.
---